Last reviewed · How we verify
VIB4920
At a glance
| Generic name | VIB4920 |
|---|---|
| Also known as | Dazodalibep, MEDI4920, dazodalibep |
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- CD40L Antagonism in Rheumatoid Arthritis (RA) (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity (PHASE3)
- A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State (PHASE3)
- VIBRANT: VIB4920 for Active Lupus Nephritis (PHASE2)
- A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome (PHASE2)
- A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis (PHASE1)
- A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant (PHASE2)
- A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIB4920 CI brief — competitive landscape report
- VIB4920 updates RSS · CI watch RSS
- Amgen portfolio CI